Accoring to Netdoctor news
Scientists have discovered that the way prostate cancer develops in men with a faulty ‘breast cancer gene’ is the same by which breast cancer develops in women with the same gene fault.
Cancer Research UK-funded scientists at the Institute of Cancer Research (ICR) identified early genetic changes that accumulate over time and lead to cancer in mice lacking the BRCA2 gene in their prostate gland.
The finding that both diseases develop the same way in men and women with a faulty BRCA2 gene suggests that breast cancer drugs may be effective against hereditary prostate cancer.
Lead author Dr Amanda Swain, from the Section of Gene Function and Regulation at the ICR, said: ‘The discovery that BRCA2 alterations play the same role in the development of hereditary prostate cancer as they do in breast cancer is an important step.
‘This sheds light on the relationship between the two conditions and could help highlight overlapping areas where similar treatments could be used to treat both.’
Dr Lesley Walker, director of cancer information at Cancer Research UK, said the findings in the journal PLoS Genetics suggest that breast cancer drugs called PARP inhibitors may also be effective against prostate cancer.
‘While we’ll need to see the results from more patients before we know if this drug could be used in men with this type of prostate cancer, this discovery shows that it’s an exciting possibility,’ he added.
Almost 45,700 women are diagnosed with breast cancer in the UK each year, while prostate cancer accounts for about 36,000 cancer diagnoses each year.